|
Journal of Lipid Research, Vol. 43, 1450-1457, September 2002
Copyright © 2002 by Lipid Research, Inc.
ApoC-III gene polymorphisms and risk of coronary artery disease
Oliviero Olivieri1,*,
Chiara Stranieri ,
Antonella Bassi ,
Barbara Zaia*,
Domenico Girelli*,
Francesca Pizzolo*,
Elisabetta Trabetti ,
Suzanne Cheng**,
Michael A. Grow**,
Pier Franco Pignatti* and
Roberto Corrocher*
* Unit of Internal Medicine, Institute of Clinical Chemistry, University of Verona, Verona, Italy
Department of Clinical and Experimental Medicine, Section of Biology and Genetics, Institute of Clinical Chemistry, University of Verona, Verona, Italy
Department of Mother and Child, and Biology-Genetics, Institute of Clinical Chemistry, University of Verona, Verona, Italy
** Department of Human Genetics, Roche Molecular System, Alameda, CA, USA
1 To whom correspondence should be addressed. e-mail: oliviero.olivieri{at}univr.it
Several polymorphisms in the apolipoprotein C-III (apoC-III) gene have been associated with hypertriglyceridemia, but the link with coronary artery disease risk is still controversial. In particular, apoC-III promoter sequence variants in the insulin responsive element (IRE), constitutively resistant to downregulation by insulin, have never been investigated in this connection. We studied a total of 800 patients, 549 of whom had angiographically documented coronary atherosclerosis, whereas 251 had normal coronary arteriograms. We measured plasma lipids, insulin, apoA-I, apoB, and apoC-III and assessed three polymorphisms in the apoC-III gene, namely, T-455C in the IRE promoter region, C1100T in exon 3, and Sst1 polymorphic site (S1/S2) in the 3' untranslated region. Each variant influenced triglyceride levels, but only the T-455C (in homozygosity) and S2 alleles influenced apoC-III levels. In coronary artery disease (CAD) patients, 18.6% were homozygous for the -455C variant compared with only 9.2% in CAD-free group (P < 0.001).
In logistic regression models, homozygosity for -455C variant was associated with a significantly increased risk of CAD (OR = 2.5 and 2.18 for unadjusted and adjusted models, respectively) suggesting that it represents an independent genetic susceptibility factor for CAD.
Abbreviations: CAD, coronary artery disease; IRE, insulin response element; TG, triglyceride Supplementary key words lipids risk factors insulin

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
E. A Ruiz-Narvaez, F. M Sacks, and H. Campos
Abdominal obesity and hyperglycemia mask the effect of a common APOC3 haplotype on the risk of myocardial infarction,
Am. J. Clinical Nutrition,
June 1, 2008;
87(6):
1932 - 1938.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. N. Thu, T. T. T. Mai, R. Ohmori, M. Kuroki, N. V. Chuyen, N. T. K. Hung, M. Kawakami, and K. Kondo
Plasma Triglyceride and HDL-Cholesterol Concentrations in Vietnamese Girls Are Affected by Lipoprotein Lipase, but Not Apolipoprotein CIII Polymorphism
J. Nutr.,
June 1, 2006;
136(6):
1488 - 1492.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. A. Ruiz-Narvaez, Y. Yang, Y. Nakanishi, J. Kirchdorfer, and H. Campos
APOC3/A5 haplotypes, lipid levels, and risk of myocardial infarction in the Central Valley of Costa Rica
J. Lipid Res.,
December 1, 2005;
46(12):
2605 - 2613.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-M. Guettier, A. Georgopoulos, M. Y. Tsai, V. Radha, S. Shanthirani, R. Deepa, M. Gross, G. Rao, and V. Mohan
Polymorphisms in the Fatty Acid-Binding Protein 2 and Apolipoprotein C-III Genes Are Associated with the Metabolic Syndrome and Dyslipidemia in a South Indian Population
J. Clin. Endocrinol. Metab.,
March 1, 2005;
90(3):
1705 - 1711.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Olivieri, N. Martinelli, M. Sandri, A. Bassi, P. Guarini, E. Trabetti, F. Pizzolo, D. Girelli, S. Friso, P. F. Pignatti, et al.
Apolipoprotein C-III, n-3 Polyunsaturated Fatty Acids, and "Insulin-Resistant" T-455C APOC3 Gene Polymorphism in Heart Disease Patients: Example of Gene-Diet Interaction
Clin. Chem.,
February 1, 2005;
51(2):
360 - 367.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. Cohn, B. W. Patterson, K. D. Uffelman, J. Davignon, and G. Steiner
Rate of Production of Plasma and Very-Low-Density Lipoprotein (VLDL) Apolipoprotein C-III Is Strongly Related to the Concentration and Level of Production of VLDL Triglyceride in Male Subjects with Different Body Weights and Levels of Insulin Sensitivity
J. Clin. Endocrinol. Metab.,
August 1, 2004;
89(8):
3949 - 3955.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Olivieri, A. Bassi, C. Stranieri, E. Trabetti, N. Martinelli, F. Pizzolo, D. Girelli, S. Friso, P. F. Pignatti, and R. Corrocher
Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease
J. Lipid Res.,
December 1, 2003;
44(12):
2374 - 2381.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W.-m. R. Wong, E. Hawe, L. K. Li, G. J. Miller, V. Nicaud, L. A. Pennacchio, S. E. Humphries, and P. J. Talmud
Apolipoprotein AIV Gene Variant S347 Is Associated With Increased Risk of Coronary Heart Disease and Lower Plasma Apolipoprotein AIV Levels
Circ. Res.,
May 16, 2003;
92(9):
969 - 975.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|